Zevra Therapeutics Inc (FRA:1GDA)
€ 4.22 -0.22 (-4.95%) Market Cap: 177.71 Mil Enterprise Value: 169.84 Mil PE Ratio: 0 PB Ratio: 3.90 GF Score: 50/100

Zevra Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 16, 2023 / 07:05PM GMT
Release Date Price: €3.94 (+2.60%)
Yinglu Zhang
RBC Capital Markets - Analyst

I think we can get started. I'm Yinglu Zhang, one of the biotech equity research analysts here at RBC Capital Markets. And we're pleased to have Zevra Therapeutics with us today.

Joining us is LaDuane Clifton, Chief Financial Officer. LaDuane, I'll turn it over to you. And thank you for joining us.

LaDuane Clifton
Zevra Therapeutics, Inc. - CFO, Secretary, & Treasurer

Thank you, Yinglu. And good afternoon, everyone. We appreciate you attending our presentation today.

Zevra Therapeutics is a rare disease therapeutics company with a robust pipeline and multiple near-term catalysts and a strong balance sheet to support reaching our objectives. Formerly known as KemPharm, we recently changed our name to Zevra, which is Greek for zebra. The zebra is the internationally recognized symbol of the rare disease community, and by taking that name, Zevra, we have committed ourselves to the mission of bringing new therapies to patients with significant unmet needs.

On this first slide, you can

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot